Curocell Income Statement

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Cost of Revenue	16.33	10.49	14.19
Gross Profit	-16.33	-10.49	-14.19
Selling, General & Admin	4,628	4,632	3,821
Research & Development	32,736	31,864	27,191
Amortization of Goodwill & Intangibles	54.88	3.87	1.5
Other Operating Expenses	88.43	14.51	11.22
Operating Expenses	37,610	36,614	31,116
Operating Income	-37,627	-36,624	-31,130
Interest Expense	-3,687	-2,603	-2,431
Interest & Investment Income	453.91	938.26	617.54
Currency Exchange Gain (Loss)	-15.25	-24.34	-14.64
Other Non Operating Income (Expenses)	1,617	83.35	3,305
EBT Excluding Unusual Items	-39,258	-38,230	-29,652
Gain (Loss) on Sale of Assets	1.24	-8.18	-11.24
Pretax Income	-39,257	-38,238	-29,664
Income Tax Expense	1.1	1.1	-88.73
Net Income	-39,258	-38,239	-29,575
Net Income to Common	-39,258	-38,239	-29,575
Shares Outstanding (Basic)	14	14	12
Shares Outstanding (Diluted)	14	14	12
Shares Change (YoY)	3.98%	18.10%	-
EPS (Basic)	-2755.02	-2736.20	-2499.18
EPS (Diluted)	-2755.02	-2736.20	-2499.18
Free Cash Flow	-30,968	-28,863	-46,428
Free Cash Flow Per Share	-2173.29	-2065.28	-3923.32
EBITDA	-31,480	-30,289	-26,424
D&A For EBITDA	6,146	6,335	4,706
EBIT	-37,627	-36,624	-31,130
Advertising Expenses	-	43.48	45.38

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.